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ABSTRACT 
MEHUL GADHIA: Campylobacter rectus Virulence And The Effects Of 
Virulence In The Pregnant Mouse Model 
(Under the direction of Dr. Offenbacher) 
 
 
 
 Previous studies in the mouse model have reported that maternal infection with 
Campylobacter rectus, a periodontal pathogen, is associated with intrauterine fetal growth 
restriction. To that end, we hypothesized that maternal immunization prior to challenge with 
C. rectus would protect the fetus from growth restriction.  Prior to mating, mice in one 
treatment arm received immunization via an intra-chamber challenge of heat-killed C. rectus 
314.  On gestation day (Gd) 7.5, pregnant mice in the treatment groups received an intra-
chamber challenge of live C. rectus at concentrations of 109 CFU/ml.  Pregnant mice were 
sacrificed on Gd 16.5 and fetuses evaluated for weight, and crown-rump length.  Maternal 
serum was collected and maternal antibody response was evaluated.  Fetuses from the C. 
rectus challenged group had shorter crown-rump lengths and weighed significantly less than 
the immunized group and the control group.  Maternal serum of the immunized group 
displayed marked elevations of IgG antibody to C. rectus compared to the non-immunized 
and control group.  In conclusion, immunization of pregnant dams with heat-killed C. rectus 
provides a robust maternal IgG response and protects against fetal growth restriction.  
 In addition, C. rectus virulence factors that may have a possible role in fetal growth 
restriction were investigated.  The genes peb4, cadF, cdtB and ciaB that have been identified 
as virulence genes and sequenced in other Campylobacter species were examined for their 
 iii
presence in C. rectus.  To that end, the genome sequences of 4 Campylobacter spp. (C. jejuni, 
C. lari, C. coli and C. upsaliensis) were used to design degenerate oligonucleotide primers to 
attempt detection and isolation of these genes in C. rectus.  Although a match was not found 
at the nucleotide level, investigation of matches at the protein level revealed similarities with 
cytochrome c552 of C. jejuni RM1221, NADP-dependent malic enzyme from C. fetus subsp. 
fetus and mannose-1-phosphate guanylyltransferase/mannose-6-phosphate isomerase from C. 
fetus subsp. fetus.  This is significant for future attempts to obtain genomic sequences from C. 
rectus and warrants further study.  
 iv
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REVIEW OF THE LITERATURE 
 
Adverse Pregnancy outcomes 
Despite advances in prenatal care, the occurrence of adverse pregnancy outcomes, 
which include spontaneous preterm births (SPB) and associated low birth weight (LBW) 
infants has not decreased in decades 1, 2.  These advances include extensive use of tocolytic 
drugs such as α-adrenergic agents, magnesium sulfate, prostaglandin synthase inhibitors and 
calcium channel blockers administered to arrest premature contractions 3.  Even with 
intervention, SPB (defined as delivery at less than 37 weeks of gestation) accounts for about 
10 percent of all live births and often results in LBW (defined as infants born less than 2,500 
grams or about 5.5 lbs) which is a significant cause of infant mortality 4.  This subset of 
deliveries is referred to as premature low birth weight (PLBW).  PLBW is an economic, as 
well as a societal burden.  The annual cost of treating PLBW infants in intensive care units is 
more than five billion dollars.  Moreover, PLBW has been associated with long term 
morbidity for the survivors including respiratory distress, cerebral palsy and learning 
disabilities 4.  Traditional risk factors for adverse pregnancy outcomes include poor overall 
maternal health, previous preterm birth, smoking, alcohol consumption, maternal emotional 
stress and infection 3. 
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Infection, inflammation and adverse pregnancy outcomes 
Support for the role of infection in adverse pregnancy events comes from many 
sources including the fact that many biological markers for preterm labor are also the same 
biomarkers of infection 5-7.  Gibbs in 2001 3 reviewed the possible association between 
adverse pregnancy outcomes and infection/inflammation and summarized the following:  
1)histological chorioamnionitis is increased in preterm births; 2)clinical infection is increased 
after preterm birth; 3)there are significant associations of lower genital tract organisms and 
infections with preterm birth or preterm premature rupture of the membranes; 4)there are 
positive cultures of amniotic fluid or membranes from some patients with preterm labor and 
preterm birth; 5)there are markers of infections in preterm birth; 6)bacteria or their products 
induce preterm birth in animal models.   
In humans, some infectious agents, including rubella, Toxoplasma and Treponema, 
have been shown to be able to cross the placental barrier, leading to the induction of fetal 
immunological responses to these infecting agents 8-10.  Compromise of the placental barrier is 
extremely serious since the developing fetus lacks a fully competent immune system to fend 
off infections.   
Maternal-fetal transfer of immunoglobulins begins around the 17th week of gestation 
and gradually increases in proportion to gestational age.  It is generally accepted that the only 
antibody to cross the placenta is Immunoglobulin G.  IgM, IgA and IgE have not been shown 
to be transferred 11.  Additional support for the involvement of infectious agents in this 
pathology is provided in veterinary sciences where it is well established that transient 
infertilities, spontaneous abortions and premature births in animals are often caused by 
various bacteria and their products. 
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Periodontal disease and adverse pregnancy outcomes 
Periodontal disease is often described as a complex bacterial infection that affects the 
supporting structures of the teeth.  This ubiquitous disease has been defined as a “specific 
mixed infection which causes periodontal destruction in the appropriately susceptible host” 12.  
Recent evidence suggests an association between periodontal disease and adverse pregnancy 
outcomes 13-15.  Epidemiological evidence suggests that pregnant women with periodontal 
disease are seven times more likely to have preterm labor than their periodontally healthy 
counterparts 16. 
Studies with pregnant rodent models have demonstrated that low-grade challenges 
with oral organisms during pregnancy resulted in impaired fetal growth. This was 
demonstrated using a chronic subcutaneous infection model with Porphyromonas gingivalis 
or Campylobacter rectus and also in a model of experimental periodontitis 16-19.  Since there 
are no animal models of preterm birth, these data provide important proof-of-concept 
experiments that raise the possibility that distant, low grade oral infections might also trigger 
inflammation of the human maternal-fetal unit in a manner analogous to that seen with 
reproductive tract infections. 
Molecular evidence for an association between periodontal disease and adverse 
pregnancy events comes from the analysis of maternal and fetal antibody response to 
periodontal pathogens. A strong maternal IgG response to the “Red” complex subgingival 
plaque organisms comprised of the pathogens Porphyromonas gingivalis, Tannerela 
forsythensis and Treponema denticola protects the fetus from exposure to these oral bacteria.  
A decreased maternal IgG response to “Red” cluster organisms is correlated with an increased 
exposure of the fetus to the “Orange” cluster of subgingival plaque organisms of which C. 
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rectus is a member.  Exposure of the fetus to C. rectus, as indicated by a strong fetal IgM 
response to this bacterium, is associated with an elevated risk of adverse pregnancy outcomes 
20. 
 
Campylobacter Species 
History and taxonomy 
In 1963, Sebald and Véron 21 transferred V. fetus and V. bubulus into a new genus, 
Campylobacter, due to their low DNA base composition, their microaerophilic growth 
requirements, and their nonfermentative metabolism.  This is considered the creation of the 
genus Campylobacter.  Ten years later, Véron and Chatelain 22 reported four distinct species 
in the genus: Campylobacter fetus (the type species), Campylobacter coli, Campylobacter 
jejuni, and Campylobacter sputorum.  More names were introduced through the years and 
during the past decade, the taxonomy of Campylobacter has undergone drastic changes.  The 
two main reasons for this phenomenon are the increased interest in Campylobacter-like 
organisms and the drastic evolution of bacterial taxonomy due to technological advances in 
molecular biology, biochemistry and affiliated disciplines.  While previous classification 
systems were based mainly on biochemical and morphological criteria, present-day 
classifications are primarily phylogeny based since they are constructed around a backbone 
derived from similarity studies of highly conserved macromolecules such as rRNA genes 23.  
These rRNA homology studies evaluated and revised bacterial classification schemes based 
on the degree of rRNA cistron similarity.   
In 1987, Romaniuk et al. 24 and Lau et al. 25 presented the first phylogenetic data on 
Campylobacter species.  They compared partial 16S rRNA sequences of C. fetus, C. jejuni, C. 
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coli, C. lari, C. sputorum, and C. pylori strains and found that these species formed a 
previously undescribed bacterial lineage, which related to other gram-negative bacteria only 
by very deep branching.   
In 1991, Vandamme et al. 26 proposed a complete revision of the taxonomy and 
nomenclature of the genus Campylobacter and related bacteria after an extensive DNA-rRNA 
hybridization study.  The genus was restricted to the rRNA homology cluster containing C. 
fetus, the type species of the genus Campylobacter. Among others, the generically misnamed 
Wolinella recta was included in the emended genus as Campylobacter rectus. 
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Campylobacter rectus Virulence 
Campylobacter rectus, formerly Wolinella recta 26, is a putative, gram-negative, 
anaerobic, motile bacterium which is associated with several forms of human periodontal 
diseases 27-30.  Although there is a limited amount of information available concerning the 
molecular mechanisms and genetic characteristics of C. rectus, some genes responsible for its 
pathogencity have been identified.  The surface layer (S-layer) and cytotoxic activity have 
been characterized and thought to be its major virulence factors.  This S-layer protein is 
assumed to be involved in resistance of C. rectus to phagocytic uptake and to bactericidal 
activity of serum 31, 32.  Recently, the gene encoding the S-layer protein (crs) has been 
sequenced 32.  The cytotoxic activity associated with C. rectus was suggested to be due to a 
Figure 1.  Phylogenetic tree of the family 
Campylobacteraceae and its closest phylogenetic neighbors, 
the genera Helicobacter and Wolinella, based on the percent 
16S rRNA gene sequence similarity.  The scale represents a 
10% sequence similarity.  (Adapted from:  Nachamkin and 
Blaser, 2000. Campylobacter, 2nd Edition) 
 7
pore-forming protein toxin belonging to the RTX (repeats in the structural toxin) family 33.  
Two closely related genes, csxA and csxB (for C. rectus S-layer and RTX protein) have been 
cloned from C. rectus and characterized 34. 
 
S-layer 
The paracrystalline cell surface layer (S-layer) appears to be composed of a single 
protein 35, 36. These S-layer proteins form regularly arranged structures on the outer surface of 
various bacteria. They are assumed to play a role in virulence of several pathogens by 
rendering the bacteria resistant to complement killing and providing structures for adherence 
to host cells 37.  Although the first 15 amino acids of the S-layer proteins are identical in 
several strains of C. rectus, the molecular mass of the S-layer protein varies from 150 to 166 
kDa among strains 38-40.  By peptide analysis, Nitta et al. 38 have also reported that there is 
internal sequence heterogeneity between the S-layer proteins from strains 314 and ATCC 
33238.   
Evidence that the C. rectus S-layer is a virulence factor stems from studies of a strain 
of C. rectus that lost its S-layer during long-term in vitro subculture 40.  It was reported that 
the S-layer negative bacteria were more adherent to human gingival fibroblasts than were 
other strains of C. rectus with intact S-layers 40.  In addition, strains which had been passaged 
15 to 17 times in vitro formed smaller lesions in a mouse abscess model for soft tissue 
destruction than did low-passage C. rectus strains 41.  These studies suggest that the C. rectus 
S-layer helps the organism evade host defense mechanisms. 
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csx 
The cytotoxic activity of gram-negative bacteria such as that proposed for C. rectus 42 
is often due to pore-forming protein toxins belonging to the family of RTX (repeats in the 
structural toxin) proteins.  RTX toxins, which include the -hemolysin (HlyA) of Escherichia 
coli 43, the leukotoxins (LktA) of Pasteurella haemolytica 44, AaltA of Actinobacillus 
actinomycetemcomintans 45, the cytotoxins ApxIA, ApxIIA, and ApxIIIA of Actinobacillus 
pleuropneumoniae 46, and the adenylate cyclase CyaA of Bordetella pertussis 47, are the major 
virulence factors associated with these pathogens 48, 49.   
Campylobacter rectus was suggested to contain genes encoding RTX proteins as 
shown by Kuhnert et al.42.  Furthermore, Gillespie et al. 33 described a cytotoxic fraction of 
C. rectus which reacted serologically with antiserum directed against leukotoxin of 
A. actinomycetemcomitans.  Recent literature described the presence of two new genes in 
C. rectus coding for bistructural S-layer-RTX proteins named csxA and csxB (C. rectus S-
layer-RTX protein) 34.  This study reported that these genes that code for csx proteins appear 
to be bi-functional and possess two structurally different domains. The N-terminal part shows 
similarity with S-layer protein, especially crs of C. rectus.  The C-terminal part comprising 
most of csxA and csxB is a domain with 48 and 59 glycine-rich canonical nonapeptide repeats, 
respectively, arranged in three blocks. Purified recombinant csx peptides bind Ca2+.  These are 
characteristic traits of RTX toxin proteins.  The S-layer and RTX domains of csx are separated 
by a proline-rich stretch of 48 amino acids. Interestingly, all C. rectus isolates studied in this 
report contained copies of either the csxA or csxB gene or both.  Also, csx genes were absent 
from all other Campylobacter species examined. 34 
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Campylobacter jejuni, C. coli and C. fetus Virulence 
It is widely accepted that cell adherence, invasive capabilities and toxin production by 
Campylobacter is multifactorial and several potential virulence determinants have been 
proposed 50, 51. 
 
Campylobacter adherence 
In order for this pathogenic bacterium to evade the host’s defensive mechanisms, 
establish an infection, and damage host cells, it must first adhere to the host tissue.    Bacterial 
adherence is mediated by bacterial cell surface structures called adhesins, which recognize 
specific receptors on the particular host cell surface.  A number of outer-membrane adhesion 
proteins have been identified.  In C. jejuni, the best-characterized adhesins to date include 
cadF and peb1 52-56. 
cadF 
The target of the cadF adhesin is fibronectin (Fn), a component of the extracellular 
matrix 52.  Fn appears to be a common host cell target and numerous pathogens, including C. 
jejuni 52, 53, 54, 57, Staphylococcus aureus 58, 59, Streptococcus pyogenes 60, 61, Salmonella 
enterica serovar Enteritidis 62, Escherichia coli 63, 64, Neisseria gonorrhoeae 65, 
Mycobacterium avium 66, and Treponema species 67-69, possess Fn binding ability. 
The binding of Campylobacter jejuni to fibronectin (Fn), is mediated by a 37 kDa 
outer-membrane protein termed cadF for Campylobacter adhesion to fibronectin 52.  The 
specificity of C. jejuni binding to Fn, via the cadF gene, was demonstrated using antibodies 
reactive against Fn and cadF 70.  Also, consistent with previous articles from this group of 
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authors, it has been reported that cadF gene and protein is conserved among C. jejuni and C. 
coli isolates 53, 54. 
peb1-4 
The purification of four proteins from glycine-extracted material of C. jejuni has been 
described 55.  These four proteins have molecular masses of 28, 29, 30, and 31 kDa and are 
named PEB1, PEB2, PEB3, and PEB4, respectively.  The importance of these proteins in 
adherence and invasion is reported in the literature.   
The PEB1 protein is encoded by the peb1A locus.  A C. jejuni peb1A null mutant 
exhibited a 50- to 100-fold reduction in binding and a 15-fold reduction in internalization to 
HeLa cells compared to the C. jejuni parental isolate 56.  This study also reported that the 
mutant exhibited a reduction in the duration of mouse intestinal colonization compared to the 
parental isolate. 
 
Campylobacter invasion 
ciaB 
Previous work has demonstrated that C. jejuni synthesizes a set of proteins during 
coculture with epithelial cells, a subset of which are secreted. The secreted proteins have been 
collectively referred to as Campylobacter invasion antigens (cia proteins) and the gene 
identified was named ciaB 54.  These proteins appear to be responsible for invasion of the 
organism into mammalian cells 71.  Specifically, insertional mutagenesis of the ciaB gene 
encoding a 73-kDa secreted protein (CiaB) results in a significant reduction in the number of 
C. jejuni cells internalized into mammalian cells compared to a C. jejuni wild-type isolate. 
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The absence of the ciaB protein secretion in the C. jejuni ciaB mutant is specific, as the 
invasive phenotype of this organism is restored by complementation in trans with the ciaB 
gene 71. 
 
Campylobacter toxicity 
cdtB 
The best characterized of the toxins attributed to Campylobacter spp. is the cytolethal 
distending toxin (CDT).  Johnson and Lior first reported CDT production by Campylobacter 
72.  They assayed over 700 Campylobacter strains, including 583 C. jejuni, 109 C. coli, 16 C. 
lari, and 7 C. fetus strains for CDT activity.  Approximately 40 % of each of these species 
was found to produce active CDT and no correlation was found between CDT production, 
serotype, biotype or country of origin of the tested strains.  They also reported that CDT 
activity in culture supernatants caused several cultured cell lines, including HeLa and Vero 
cells, to become slowly distended over a 2- to 4-day period, after which the cells disintegrated 
72.  The C. jejuni cdt genes have been cloned and sequenced 73.  CDT activity is encoded by 
three adjacent genes, cdtA, cdtB, and cdtC, which encode proteins predicted to have molecular 
weights of about 30,000, 29,000, and 21,000, respectively 73, 74.  In the last decade, the gene 
encoding CDT, cdtB, has been found in most Campylobacter species 73-78.  Homologues of 
cdtB and CDT activity have also been found in several serotypes of E. coli 79-83 and 
enterohepatic Helicobacter species 84, 85.  Other gram-negative bacteria harboring the cdtB 
gene and producing CDT activity include the periodontopathogenic bacterium Actinobacillus 
Actinomycetemcomitans 86-89. 
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The mechanism of CDT activity is reported to involve the G2/M cell-cycle phase of 
certain target eukaryotic cells.  At this phase, the CDT toxin causes progressive cytoplasmic 
and nuclear distension accompanied by increased DNA contents, leading to growth arrest and, 
ultimately, cell death 78, 82, 90, 91. 
  
SPECIFIC AIMS AND HYPOTHESES 
 
Despite epidemiological, biological and molecular evidence associating the oral 
infectious agent Campylobacter rectus and adverse pregnancy outcomes, certain lingering 
questions must be addressed.  Namely, how is this organism evading the host defense and 
infecting the fetus and is there a possibility to prevent this from happening. 
It is our hypothesis that immunization with heat-killed C. rectus 314 will offer 
protection to fetal growth restriction in the murine model.  Specifically, our aims were to 
study the possibility of protecting the fetus from growth restriction by mean of maternal 
immunization.  Also, we plan to examine the maternal IgG antibody response to C. rectus 
infection in immunized mice versus non-immunized mice. 
  To investigate the possibility of fetal protection, we utilized an established remote 
subcutaneous chamber model that has been used to study fetal growth restriction by C. rectus 
19, 92.  These studies have reported fetal growth restriction induced by maternal C. rectus 
infection and the outline of our experiment mirrored these studies.   We compared 3 groups of 
mice: (1) pregnant mice immunized with heat-killed C. rectus and then challenged with live 
C. rectus, (2) pregnant mice not pre-immunized but challenged with live C. rectus and (3) a 
control group not immunized or challenged.  Maternal antibody response and fetal growth 
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restriction were compared between these groups to evaluate possible protection from adverse 
pregnancy outcomes.   
Also, it is our hypothesis that C. rectus contains one or more of the virulence genes 
already identified in other Campylobacter species.  Specifically, our aim was to investigate 
the presence of 4 virulence genes in the genome of C. rectus via degenerate PCR.  The 4 
genes we examined were: ciaB (Invasion protein required for invasion of epithelial cells), 
cdtB (Cytolethal distending toxin, known to arrest mammalian cells during the cell cycle), 
cadF (Fibronectin binding protein important for cell binding) and peb4 (responsible for 
adhesion).  All of the chosen genes are conserved in C. jejuni, C. coli, C. lari, and C. 
upsaliensis while 3 of 4 are conserved in C. fetus (ciaB, cdtB and cadF).  To investigate their 
presence in C. rectus, we first designed degenerate primers for these genes from the genome 
of C. jejuni 78-14 and C. coli.  Prior to running the degenerate PCR, we first tested the 
authenticity of the template DNA and the degenerate primers by means of a positive control 
PCR.  After confirmation that our template DNA was C. rectus and our degenerate primers 
worked, PCR of C. rectus with these degenerate primers was done.  The PCR products 
obtained were gel extracted and sequenced. 
 
 
  
 
MATERIALS AND METHODS 
 
Effects of Immunization in the Pregnant Mouse Model 
 
 
Experimental Groups 
 Three experimental groups were studied: Group A consisted of mice that received 
immunization prior to challenge with C. rectus 314.  Group B consisted of mice that only 
received challenge with C. rectus 314 while Group C, the control group, only received PBS 
(phosphate buffered saline).  There were 5 female mice in test group A, 32 mice in test group 
B and 27 mice in the control group.  
 The timeline of the experimental protocol for chamber implantation, immunization 
with heat-killed C. rectus, challenge with C. rectus and sacrifice of pregnant mice is 
summarized in Figure 2.  Sacrifice was performed on Gd 16.5.  At that time, maternal serum 
samples were collected via cardiac puncture and the fetal weight and length were recorded. 
The experiment, data collection and serum samples for Group B and Group C was 
done and provided by Dr. Yiorgos Bobestsis and Dr. Steven Offenbacher’s laboratory. 
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Figure 2. Study design to investigate maternal immune response and fetoprotective effects of 
immunization. 
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Animal Husbandry 
All procedures were in accordance with the animal welfare guidelines and approved 
by the University of North Carolina – Chapel Hill Institutional Animal Care and Use 
Committee.  BALB/c mice (Jackson Laboratory, Bar Harbor, MI) were obtained at 4-6 weeks 
of age, and maintained under controlled, standardized conditions. The mice were housed 
under controlled and standardized conditions, with 12-hour light-dark cycles (0700-1900 
light).  Regular mouse diet and water were provided ad libitum.       
 
Chamber Implantation 
A stainless steel, open-ended cylindrical coil spring (chamber) approximately 1.0 cm x 
0.4 cm was inserted subcutaneouly into the female mice. To implant the chamber, each female 
mouse was anesthetized with 6 mg per kg xylazine (20 mg/ml) and 130 mg per kg ketamine 
hydrochloride saline solution (100 mg/ml) given in 0.1 ml with normal saline solution 
injected intra-peritoneally. 
Under anesthesia, the neck region of the mouse was shaved and disinfected with 70 % 
ethanol and betadine.  A small incision (~2 cm) was made in the skin of the back with scissors 
paralleling the line connecting the apical most point of shoulder blades and just coronal to the 
line. A cylinder shaped dissection was made sub-dermal to the right flank with a pair of 
needle holders. A sterilized chamber was placed in the dorsal lumbar region, as described by 
Genco and co workers 93.  The skin was then sutured with 4-0 silk, and the site allowed to heal 
for at least 2 weeks. 
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Bacteria Preparation for Immunization and Challenge 
C. rectus was cultured on ESTA plates.  After 5-8 days, bacteria were collected by 
gently scrapping the surface of the plate using a sterile cotton swab. The swab was then 
immersed in sterile PBS (3 ml in a sterile 15 ml conical tube) and rubbed and rotated against 
the side of the test tube to release the bacteria. The bacterial concentration was evaluated by 
spectrophotometry, with a measured OD600nm= 1 corresponding to 1 X 109 bacteria/ml. 
 
Immunization 
The immunization solution was prepared by heating the bacteria in boiling water for 
10 minutes.  Two weeks after the chamber implantation surgery, 5 mice were immunized by 
intra-chamber injection of 0.1 ml PBS containing 109 bacteria/ml of heat-killed C. rectus 314.  
Mice were then allowed to recover and build immunity for 2 weeks. 
 
Mice Breeding 
Sixty-four female mice were mated with male mice of the same strain. The mice were 
mated overnight. The next morning all female mice were removed from the male cages and 
examined for vaginal plugs. If plugs were found, that day was recorded as gestation day (Gd) 
0.5. 
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Challenge with Campylobacter rectus 
On Gd 7.5, pregnant mice in Group C (control group) received an intra-chamber 
injection of 0.1 ml PBS, while the pregnant mice in test groups A and B received an intra-
chamber injection of 0.1 ml PBS containing 109 bacteria/ml live C. rectus 314 (108 CFU). 
 
Monitoring of Animal Responses after Bacterial Challenges 
 The general response of the animals was monitored during the experimental period.  
Chamber sloughing, secondary ulceration, cachexia, body weight change before and after C. 
rectus challenge, and death were recorded if any. 
 
Animal Sacrifice and Data Collection 
Prior to sacrifice, the female mice were anesthetized with phenobarbital sodium 
solution (50 mg/ml) given in 0.1 ml increments with normal saline solution injected intra-
peritoneally.  The abdomen was opened and the uterus dissected.  The resorption sites and 
positions of viable fetuses were recorded.  Fetuses were removed from the chorioamniotic sac 
and their weight and crown-rump length were measured.  
 
Statistical Analysis 
 In order to account for the fact that the effects of immunization and challenge on 
littermates are clustered within dams, we used a mixed model method 94.  The statistical 
comparison of fetal weight between the 3 groups was evaluated with a mixed effects model 
with a fixed effect for treatment and a random effect for dam, the latter providing adjustment 
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for intralitter correlation of fetal weight.  Similar analyses were applied to fetal length.  Data 
were analyzed using statistical software (SAS Institute, Cary, NC). 
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Evaluation of Maternal Antibody Response 
 
Sample Collection 
Maternal blood was collected by cardiac puncture and stored overnight at 4 °C.  The 
blood clot was removed and serum was then separated by centrifugation at 2000 X g for 20 
minutes and then stored at -80 °C until ready for western blot analysis. 
 
Antigen Preparation, SDS-PAGE and Western Blotting 
C. rectus cells were harvested for lysate preparation from a 5-8 day old plate of C. 
rectus as described above.  The turbidity was adjusted to an OD600nm of 4.0.  Cells were then 
sonicated on ice for 20 minutes.  Equal volumes (10 microliters) of the bacterial sample were 
taken and a 1:3 dilution was made using Cell Lysis Buffer (Cell Signaling Technology, 
Beverly, MA).  The samples were centrifuged for 1 min to pellet any cell debris.  
Supernatants were transferred to another tube and 5 μl of 5 X Laemmli Buffer and 1 μl of β 
mercaptoethanol were added to each sample.  The samples were boiled for 5 min and then 
applied to 10 % Novex Tris-glycine gels (Invitrogen) and transferred to nitrocellulose 
membranes (Whatman).  Blots containing the C. rectus protein were blocked with 5 % non-fat 
milk for 1 h at room temperature.  The blots for each sample were then incubated with 
corresponding mouse sera samples (1:500 dilution) in TBST overnight at 4° C and then 
incubated with goat anti-mouse IgG horse radish peroxidase polyclonal secondary antibody 
(1:2000 dilution) in 5% non-fat milk for 1 h at room temperature.  Blots were washed with 
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TBST for 10 min at room temperature, exposed to chemiluminescence reagent (Perkin Elmer 
Western Lightning), and developed.  Equal loading of samples was verified by staining of 
blots with 0.1 % Ponceau S solution (Sigma) for 5 minutes.   
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Investigation of Virulence Genes peb4, ciaB, cadF, cdtB 
  
The study design utilized to investigate the presence of the above virulence genes in 
Campylobacter rectus is outlined in Figure 3. 
 
 
Bacterial culture of
C. jejuni, C. coli, C. rectus
DNA Extraction
PCR
Designed degenerate primers
Gel Extraction
Sequencing
Positive control (Template)
PCR of C. rectus 33238 and 314 with 
non-DP csxA, csxB, crs, H20
PCR of C. rectus 33238 and 314 
with DP peb4, cadF, cdtB, ciaB
Positive control (Primers)
PCR of C. lari and C. jejuni with DP 
peb4, cadF, cdtB, ciaB
 
 
Figure 3.  Study design to investigate possible virulence genes in C. rectus 
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Bacterial Strains and Growth  
 C. rectus ATCC 33238 and 314 were taken from frozen stocks and plated on tryptic 
soy blood agar plates (Anaerobe Systems) supplemented with formate-fumarate (pH 7.0) to 
0.3 %.  Cultures were grown for two days in a Thermo Forma Model 1025 anaerobic chamber 
with anaerobic gas mixture (5 % carbon dioxide, 10 % hydrogen, and 85 % nitrogen).  Two 
plates per strain were harvested with a sterile cotton swab into cold sterile phosphate buffered 
saline, pH 7.0 (PBS), and centrifuged at 3500 rpm (4 ºC) in a swinging bucket rotor 
(Beckman, Allegra 25R) for 15 minutes.  The supernatant was removed, 1 ml of additional 
cold PBS was added and pellets were resupended and transferred to prechilled 1.5 ml tubes.  
The 1.5 ml tubes were centrifuged in a cold microfuge at 13,000 rpm for 1 min.  The 
supernatants were removed, and the pellets frozen immediately at -70 ºC.  The pelleted 
bacteria were stored frozen at -70 ºC until they were used for DNA isolation.  Bacterial pellets 
of these organisms were kindly provided by Dr. Deborah Threadgill, The Department of 
Genetics at UNC-CH.  
 
DNA Extraction 
DNA was extracted as per the manufacturer’s instructions using the Wizard® 
Genomic DNA Purification Kit (Promega, Madison, WI). 
 
PCR 
The primers were synthesized by Operon Biotechnologies, Inc. (Huntsville, AI).  The 
design of the specific primers are listed in Table 1 and the design of degenerate primers are 
listed in Table 2.  PCR was performed using the HotStart Taq DNA polymerase Kit (Qiagen, 
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Valencia, CA) following the manufacturer’s instructions.  Specifically: 5 μl of 10X PCR 
buffer solution, 2 μl of 10 mM dNTPs, 2.5 μl of 25 mM MgCl², 1.5 μl of each primer (50 
μM), 2 μl of template DNA (100 ng), and 2.5 U of Taq polymerase were mixed and the final 
reaction volume was brought to 50 μl by adding double-distilled water.  A DNA thermal 
cycler (GeneAmp) was used for amplification using the cycling conditions listed in Table 3.  
A 15 μl sample of the amplified material was subjected to electrophoresis at 80 mV on 2 % 
TAE agarose gel.  A 100 bp DNA ladder (Promega Corporation, Madison WI, USA) was 
used as a size marker.  The gel was stained with ethidium bromide (Eugene, Oregon, USA) 
and a photograph was taken under UV light.  
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Table 1. Specific primer sequences 
 
Gene Primer Sequences (5΄~ 3΄) Annealing Temperature (°C)
Approximate 
predicted sizes (bp) 
csxA 
F 
R 
csxB 
F 
R 
crs 
F 
R 
 
TGTCCCTAACCCAGTCCCAT 
ATCGTATCGTCTCCGTCGTTA 
 
ATGTCCCTAACCCAGTCCCAT 
GATTATTGCCGCTTCCCAGAT 
 
ATGGCTTTAACACAGACACA 
CTCTTACAGTTAGTCTTAGAT 
55 
 
 
55 
 
 
52 
2000 
 
 
2000 
 
 
2000 
 
 
 
 
Table 2. Sequences of degenerate primers 
 
Gene Degenerate primer sequences (5΄~ 3΄) 
Annealing 
Temperature (°C) 
Approximate 
predicted sizes (bp) 
cdtB 
F 
R 
cadF 
F 
R 
ciaB 
F 
R 
peb4 
F 
R 
 
HACTTGGAATTTRCAAGG 
ATCBCCBRHWATCATCC 
 
AWTWGAAMTHACTCCWAC 
GCACCYTYTCTTGG 
 
CCWTTRCAARTRGGWCATC 
ARVTCHTCTTSYTCATG 
 
GAYACWGAAGTRARTGGA 
AATRATATYYTTAGCTTCTT 
45 
 
 
45 
 
 
45 
 
 
45 
 
 
500 
 
 
550 
 
 
570 
 
 
350 
 
IUB codes for mixing bases 
B= C,G OR T 
D= A,G OR T 
H= A,C OR T 
V= A,C OR G 
R= A OR G 
Y= C OR T 
K= G OR T 
M= A OR C 
S= G OR C 
W= A OR T 
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    Table 3. PCR cycling conditions 
 
Steps csx and crs primers Degenerate primers 
Initial denaturation 
Denaturation 
Annealing 
Extension 
Number of cycles 
Extension 
95°C  for 5 min 
95°C for 30s 
55°C for 30s (52 for 30s for crs) 
72°C for 1 min 
thirty times 
72°C for 7 min 
end 
95°C for 5 min 
95°C for 30 sec 
45°C 5 for 30 sec 
72°C for 1 min 
thirty times 
72°C for 7 min 
end 
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Gel Extraction 
DNA was purified from agarose gels using the Qia quick® gel extration kit (Qiagen, 
Valencia, CA) as per the manufacturer’s instructions. Five PCR products were extracted and 
submitted for sequencing. 
 
Sequencing 
Nucleotide sequencing was carried out by the UNC-CH sequencing core.  Sequences 
obtained were analyzed using the BLAST program to determine whether any homology 
existed to any known Campylobacter spp. sequences or any other organism.  
(http://www.ncbi.nlm.nih.gov/BLAST/) 
  
 
RESULTS 
 
Effects of Immunization in the Pregnant Mouse Model 
 
Data of Experimental Groups at Gd 16.5 
 Fetuses were measured and maternal serum was collected for experimental groups A, 
B and C.   The sample size of Group B and C was considerably larger than that of Group A 
regarding the number of dams and number of fetuses studied.  However, the unequal group 
sizes did not hinder evaluation of statistical significance between the groups when comparing 
fetal weight and fetal length.   
Group A (mice that received immunization prior to bacterial challenge) consisted of 5 
dams that had a total of 28 fetuses.  The mean fetal weight of this group was 0.49 gms (SE 
0.017) and the mean fetal length was 1.46 cm (SE 0.028).   
Group B (mice that did not receive immunization prior to bacterial challenge) 
consisted of 32 dams that had a total of 193 fetuses.  The mean fetal weight was 0.43 gms (SE 
0.007).  Regarding the evaluation of fetal length, data for only 27 of these dams were 
available and provided for analysis.  These 27 dams had a total of 161 fetuses and the mean 
fetal length was 1.34 cm (SE 0.012). 
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Group C/Control (mice that did not receive either immunization or bacterial challenge) 
consisted of 27 dams that had a total of 144 fetuses.  The mean fetal weight of this group was 
0.48 gms (SE 0.008)  and the mean fetal length was 1.45 cm (SE 0.012). 
 
Comparison of Fetal Weight and Fetal Length at Gd 16.5 
When comparing the mean fetal weights and length, there was a significant difference 
between group A and B and between group B and C (p<0.001).  However, there was no 
significant difference between group A and C.  The recorded fetal weight and length 
measurements at the time of sacrifice Gd 16.5 are summarized in Table 4 and graphically 
depicted in Figure 4 and 5.       
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27275Number of Dams
14416128Number of Fetuses
1.45 (0.012)1.34 (0.012)**1.46 (0.028)*Mean (SE)
Fetal Length (cm)
27325Number of Dams
14419328Number of Fetuses
0.48 (0.008)0.43 (0.007)**0.49 (0.017)*Mean (SE)
Fetal Weight 
(gram)
GROUP C
Not Immunized and 
Not Challenged 
(Control)
GROUP B
Not Immunized 
and Challenged
GROUP A
Immunized and 
Challenged
p-value < 0.001 using the Mixed model
* denotes statistical significance between Group A and B but not C
** denotes statistical significance between Group B and C, B and A 
but not between A and C  
 
Table 4.  Summary of maternal and fetal data collected.
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Figure 4.  Comparison of fetal weight at Gd 16.5.  Error bars represent the standard error of 
the mean. 
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Comparison of Fetal Length
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Figure 5.  Comparison of fetal length at Gd 16.5.  Error bars represent the standard error of 
the mean.   
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Evaluation of Maternal Antibody Response 
 
Western Blot 
 The presence and level of maternal antibody response was evaluated by the western 
blot technique and shown in Figure 6.  The results show an overall marked elevation of IgG 
antibody to Campylobacter rectus 314 proteins in maternal serum of Group A compared to 
Groups B and C.  Specifically, Group A displayed numerous bands on the blot, depicting 
antibody production for proteins of many different sizes.  These bands display vigorous IgG 
antibody binding for both large and small proteins.   
Although the maternal serum in Group B had a decreased total amount of IgG 
response compared to Group A, the blot depicts a more intense response at two sites.  These 
sites represent IgG binding to protein sizes of approximately 140 kDa and 50 kDa.  Additional 
weak bands are noted on the blot, however, they are very light (signifying minimal antibody 
response) and comparable to the light bands found in the control group.  
Equal loading of total protein along the lanes was confirmed by staining the blot with 
0.1 % Ponceau S solution as shown in Figure 7.    
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Figure 6. Western blot 
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Figure 7. Loading control - stain with 0.1 % Ponceau S solution (Sigma). 
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Investigation of Virulence Genes peb4, ciaB, cadF, cdtB 
 
PCR of Positive Control (Template) 
To confirm that the target bacterial DNA belonged to C. rectus, we carried out PCR 
for C. rectus 33238 and C. rectus 314 using specific primers for known virulence genes (csxA, 
csxB and crs).  PCR results for C. rectus 314 are displayed in Figure 8.   
Lane 1 of the 1% agarose TAE gel contains a 1 kb ladder.  Lane 2 contains a PCR 
product obtained from C. rectus DNA using specific primers for the csxA gene.  The PCR 
product amplified was the expected appropriate size of 2000 bp.  Lane 3 contains a PCR 
product obtained from C. rectus DNA using specific primers for the csxB gene.  Again, the 
expected appropriate size of 2000 bp was amplified.   Interestingly, Lane 3 contains 
substantially more product than lane 2 or lane 4.  Lane 4 contains a PCR product obtained 
from C. rectus DNA using specific primers for the crs gene.  This band also displayed 
amplification of 2000 bp.  Lane 4 displays a very light band, signifying a reduced quantity of 
product, possibly due to the annealing temperature utilized.  Lane 5 contains a “no-template” 
control.  Here, distilled water was used instead of DNA template to demonstrate that the PCR 
products obtained were not a result of contamination.  As expected, bands are not present in 
this lane.   
Due to the specific amplification of PCR products of appropriate sizes, it was deduced 
that the template DNA was C. rectus 314.  Similar results were obtained from PCR of C. 
rectus 33238 with these specific primers (not shown). 
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Figure 8.  PCR products from C.rectus 314 obtained using specific primers for csxA, csxB 
and crs genes.  The results show bands of the expected sizes of approximately 2000 bp. 
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PCR of Positive Control (Primers) 
To confirm that the newly designed degenerate primers were effective, PCR was 
carried out on template DNA from organisms from which the degenerate primers were 
designed (C. jejuni, C. lari, C. coli and C. upsaliensis).  The result of this PCR is displayed in 
Figure 9.   
Lane 1 of the 1% agarose TAE gel contains a 1 kb ladder.  Lane 2 contains PCR 
products from C. jejuni 78-14 obtained using degenerate primers for the gene peb4.  As 
expected, the products were 350 bp.  Lane 3 contains PCR products from C. jejuni 78-14 
obtained using degenerate primers for gene cadF having the expected appropriate size of 550 
bp.  Lane 4 contains PCR products from C. jejuni 78-14 obtained using degenerate primers for 
gene cdtB having the expected appropriate size of 500 bp.  Lane 5 contains PCR products 
from C. jejuni 78-14 obtained using degenerate primers for gene ciaB having the expected 
appropriate size of 570 bp. 
Lane 6 contains three distinct bands of PCR products from C. lari obtained using 
degenerate primers for gene peb4.  Although multiple bands were found, the expected 
appropriate band displaying product size of 350 bp was present.  The two other bands found 
were 200 bp and 500 bp.  Lane 7 contains PCR products from C. lari obtained using 
degenerate primers for gene cadF having the expected appropriate size of 550 bp.  Lane 8 
contains PCR products from C. lari obtained using degenerate primers for gene cdtB having 
the expected appropriate size of 500 bp.  Lane 9 contains PCR products from C. lari obtained 
using degenerate primers for gene ciaB having the expected appropriate size of 570 bp.  The 
results of this PCR show bands of the expected sizes for each gene in question. This confirms 
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that the degenerate primers are effective in amplifying the appropriate sequences from the 
organisms they were designed from.   
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Figure 9.  PCR products of C. jejuni 78-14 using degenerate primers for peb4, cadF, cdtB and 
ciaB constructed from the C. jejuni 78-14 genome are displayed in Lanes 2-5.  PCR products 
of C. lari using degenerate primers for peb4, cadF, cdtB and ciaB constructed from the C. lari 
genome are displayed in Lanes 6-9. 
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PCR of C. rectus 314 With Degenerate Primers 
After confirmation that the template DNA was from C. rectus and that the degenerate 
primers were effective in amplifying our selected virulence genes in C. jejuni and C. lari, 
PCR of C. rectus with these degenerate primers was done and the results are displayed in 
Figure 10. 
Lanes 1 and 10 of the 1% agarose TAE gel contains a 1 kb ladder.  Lanes 2, 4, 6 and 8 
contain PCR products from C. jejuni 78-14 obtained using degenerate primers for genes peb4, 
cadF, ciaB and cdtB respectively.  These results have already been established from a 
previous PCR depicted in Figure 9. and they serve as the control in this PCR.  Briefly, the 
sizes of products for lanes 2, 4, 6 and 8 are 350 bp, 550 bp, 570 bp and 500 bp respectively.   
Lane 3 contains PCR products of C. rectus 314 obtained using degenerate primers for 
peb4.  Two faint bands (low quantity of product) were obtained of approximately 800 bp and 
570 bp.  Neither band was close to the appropriate expected size of 350 bp.   
Lane 5 contains PCR products of C. rectus 314 with degenerate primers for cadF.  
Two light bands were obtained, one of which appears to be of the appropriate expected size of 
550 bp.  The other was approximately 350 bp.   
Lane 7 contains PCR products of C. rectus 314 obtained using degenerate primers for 
ciaB.  Two bands were obtained, one light and one intermediate in quantity.  Neither band 
was of the appropriate expected size of 570 bp, however, the lighter band was close to this 
size (approximately 500 bp) while the intermediate band was approximately 1000 bp. 
Lane 9 contains PCR products of C. rectus 314 obtained using degenerate primers for 
cdtB.  Two bands were obtained, one light and one strong (high in quantity).  Neither band 
was of the appropriate expected size of 500 bp, however, both bands were very close to this 
 43
size.  The lighter band appears to be approximately 600 bp and the stronger band appears to 
be approximately 400 bp. 
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Figure 10.  PCR products of C. rectus 314 and C. jejuni (control) using degenerate primers 
for genes peb4, cadF, ciaB and cdtB. 
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Sequencing and Sequence Analysis 
Five PCR products were gel extracted and sent for sequencing at UNC-CH sequencing 
core.  These included one ciaB (500 bp) from C. rectus 314, one cadF (550 bp) from C. rectus 
314, one cdtB (400 bp) from C. rectus 314 and two cdtB (500 bp and 550 bp) from C. rectus 
33238.  Four of the five PCR products submitted for sequencing yielded workable results.  
After BLAST analysis, the stretches of homology obtained were low on a nucleotide level.  
Therefore, the nucleotide sequences were translated to protein using the ExPASy program 
(www.expasy.org) and BLAST analysis was carried out.  BLAST searches of protein 
sequences found the following matches: 
• For cadF in C. rectus 314, there was 53% identity to cytochrome c552 of C. jejuni 
RM1221 based on a translated protein BLAST against the protein database. 
• For cdtB in C. rectus 314, there was a 75% identity to NADP-dependent malic enzyme 
from. C. fetus subsp. fetus. 
• For cdtB in C. rectus 33238, there was a 70% identity to NADP-dependent malic 
enzyme from C. fetus subsp. fetus. 
• For cdtB in C. rectus 33238, there was a 67% identity to mannose-1-phosphate 
guanylyltransferase/mannose-6-phosphate isomerase from C. fetus subsp. fetus. 
  
 
DISCUSSION 
 
Regarding the investigation of C. rectus virulence, the present study was designed to 
test the hypothesis that certain genes responsible for virulence that are conserved in some 
Campylobacter species are also conserved in C. rectus.  To investigate the presence of 
conserved genes, we utilized degenerate primers.  A PCR primer sequence is called 
degenerate if some of its positions have several possible bases 95.  Therefore, degenerate 
primers are particularly useful in amplifying homologous genes from different organisms 96-98.  
Homologous genes display regions where they are highly conserved and also regions where 
they have evolved and are divergent.  Degenerate primers are designed within the conserved 
regions of the target gene, accounting for random variations that have occurred over time.  
Due to their non-specificity, degenerate primers can be used to isolate orthologous genes 
encoding proteins that belong to known protein families 97. 
To that end, degenerate primers were formulated for previously characterized 
virulence genes in C. jejuni, C. lari, C. coli and C. upsaliensis.  In our investigation of these 
genes in C. rectus, we obtained 5 PCR products that were suitable for sequencing.  Four of 
these matched known genes in the BLAST database.  DNA degradation, insufficient DNA or 
sequencing errors could account for the failure of one of these samples to be read.   
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The 4 PCR products that could be read were believed to be cadF or cdtB (cad C.r 314, 
cdtB C.r 314, 2 x cdtB C.r 33238).  Two PCR products were investigated for cdtB C.r 33238 
as it was not known which band potentially contained the sequences for cdtB. 
BLAST analysis of our nucleotide sequences failed to find any strong matches for 
known genes in the database.  One possible reason may be that the target DNA sequence from 
C. rectus may be very far removed from other Campylobacter species.  They may share the 
same gene but may not be similar at the nucleotide level. 
The reason amino-acid sequences were analyzed after DNA analysis failed was that 
different combination of bases can code for the same amino acid.  Therefore, we may see a lot 
of diversity at the nucleotide level but that may not hold true at the protein level.  Generally, it 
is found that amino acid sequences are more conserved than nucleotide sequences.  To that 
end, if a match is not found at the nucleotide level, it is worthwhile to investigate matches at 
the protein level as there may be decreased diversity.  We had a PCR product the same size as 
the size of cadF in C.r 314 and a protein BLAST revealed an identity with cytochrome c552 
of C. jejuni RM1221.  Although we did not get a match for cadF as we expected, we did get a 
protein match with Campylobacter jejuni.  Therefore, although we did not amplify the cadF 
gene from C. rectus, we did amplify a sequence belonging to C. rectus as these protein 
sequences match with those of other Campylobacter species.  As there is minimal sequence 
data relating to the C. rectus genome, any sequences obtained from this organism are 
valuable.  For instance, the cytochrome c552 of C. jejuni RM1221 has not been previously 
identified in C. rectus 314.   Therefore, this is the first account of C. rectus 314 sequences that 
share similarity to cytochrome c552 of C. jejuni RM1221.  Similarly, this is the first account 
of C. rectus 314 sequences that share similarity to NADP-dependent malic enzyme and 
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mannose-1-phosphate guanylyltransferase/mannose-6-phosphate isomerase from C. fetus 
subsp. fetus. 
Previous murine model studies utilizing sensitized mice have reported significant FGR 
and adverse pregnancy outcomes upon remote subcutaneous maternal C. rectus infection 19, 92.  
The same model was used to determine the role of immunization to this organism, 
specifically, if immunization protected the fetus from these adverse events.  In addition to 
fetal measurements, maternal antibody response was evaluated via investigation of IgG in 
maternal serum. 
Overall, immunization had a significant effect on the mean fetal weight and length.  At 
the day of sacrifice Gd 16.5, the mean fetal weight and length of immunized mice were 
significantly higher than non-immunized mice.  However, these measurements were not 
significantly different from the control mice.  The data collected from this experiment 
strongly suggests immunization protects against FGR, as immunized mice do not display FGR 
when challenged with C. rectus 314 and their fetuses have the same weight and length as mice 
given PBS.       
Further evidence of protection is seen in the IgG response of mice in the experimental 
groups.  As depicted by western blotting, immunized mice displayed a robust IgG response to 
many sizes of C. rectus proteins compared to non-immunized and the control mice.  The 
reason Group-A mice display numerous bands on the blot is likely due to receiving heat-killed 
C. rectus 314.  Boiling and sonication effectively lysed the organism and therefore, its inner 
and outer proteins were exposed.  This facilitated recognition and subsequent antibody 
production of multiple C. rectus proteins of many different sizes.  In comparison, Group-B 
mice were only exposed to intact C. rectus 314 and therefore recognized and produced 
 49
antibodies of substantially fewer proteins of the outer membrane.  Specifically, the western 
blot displays strong bands for mainly two C. rectus proteins of size 150 kDa and 55 kDa.  
This result is suggestive of antibody recognition of the C. rectus S-layer surface protein, 
described as having a molecular mass of 150-166 kDa. 
The specific size of proteins that may play a large role in virulence of C. rectus is best 
explained by assessing the differences between Group A and Group B in production of IgG 
for these various protein sizes.  Therefore, the proteins recognized by Group A but not 
recognized by Group B are the most likely candidates to cause FGR.  Specifically, IgG 
production against these proteins offers protection against FGR in Group A mice, while lack 
of IgG response to these proteins in Group B mice may explain the FGR in this group.  
Coincidentally, the 4 virulence genes we investigated in our experiment code for proteins of 
sizes 31 kDa (peb4), 37 kDa (cadF), 29 kDa (cdtB) and 73 kDa (ciaB).  Of these, it appears 
Group B mice only displayed a band for size 37 kDa (suggesting it may be cadF) while Group 
A mice displayed bands for all of these protein sizes.  Although we have not confirmed the 
exact sequences of these proteins, their sizes are highly suggestive of the proteins produced by 
the genes we investigated. 
  
 
CONCLUSION 
 
• Overall, the mean fetal weight and fetal length of immunized mice were 
significantly higher than those of non-immunized mice.   
•  The serum of immunized mice displayed an overall marked elevation of IgG 
antibody to C. rectus 314 proteins compared to non-immunized mice. 
•  Our data suggest that immunization with heat-killed C. rectus 314 offers 
protection from fetal growth restriction in the murine model 
• Although our degenerate PCR products did not amplify known Campylobacter 
virulence genes, the results leading up to the last few steps of the experiment were 
highly encouraging and validate further study. 
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